Jim Cramer says Coca-Cola is a buy after company ‘put on a clinic’ in latest earnings report

Jim Cramer says Coca-Cola is a buy after company ‘put on a clinic’ in latest earnings report


CNBC’s Jim Cramer explained why he believes Coca-Cola is an endurable, investable stock on the heels of its latest quarterly earnings report.

“Coca-Cola put on a clinic, showing you how a seasoned management team can overcome just about any challenge you might throw at them. That’s long-lasting strength. That’s a great stock to put away,” the “Mad Money” host said.

Coca-Cola reported better-than-expected quarterly earnings and revenue on Monday.

Shares of Coke rose 1.06%, notching a new 52-week high earlier in the day.

“The quarter’s a reminder that sometimes you just want to own the best of breed companies in unassailable positions. … It’s not that Coca-Cola’s got no problems — they’re dealing with the same issues as everyone else — it’s that they’ve been able to safely navigate their way through the thicket,” Cramer said.

He attributed Coke’s success to the popular Topo Chico Hard Seltzer, its DoorDash collaboration and other efforts to gain market share and get products to customers.

Coke said it is seeing higher costs for core supplies like high fructose corn syrup and aluminum. But Cramer noted “the good news is that the companies that make cans are finally adding capacity after holding back for a long time, mostly because of Covid.” 

“If we’re going to get out of this inflationary spiral, we either need to see lots of companies adding capacity, or the Federal Reserve will have to crush the economy. When it comes to Coke, obviously its suppliers boosting their production is what really matters,” he said.



Source

Novo Nordisk shares rise 5% after Wegovy obesity pill has ‘solid’ launch
Business

Novo Nordisk shares rise 5% after Wegovy obesity pill has ‘solid’ launch

A pharmacist displays a box of Wegovy pills at a pharmacy in Provo, Utah, US, on Thursday, Jan. 15, 2026. George Frey | Bloomberg | Getty Images Shares of Novo Nordisk rose more than 5% on Friday after early prescription data showed an encouraging start to the U.S. launch of the company’s new GLP-1 pill […]

Read More
Trump’s proposed ban on buying single-family homes introduces uncertainty for family offices
Business

Trump’s proposed ban on buying single-family homes introduces uncertainty for family offices

Single-family homes in a residential neighborhood in Miramar, Florida, Oct. 27, 2022. Joe Raedle | Getty Images News | Getty Images A version of this article first appeared in CNBC’s Inside Wealth newsletter with Robert Frank, a weekly guide to the high-net-worth investor and consumer. Sign up to receive future editions, straight to your inbox. Private investment […]

Read More
College students and teens could be fueling the prediction markets boom
Business

College students and teens could be fueling the prediction markets boom

A version of this article first appeared in the CNBC Sport newsletter with Alex Sherman, which brings you the biggest news and exclusive interviews from the worlds of sports business and media. Sign up to receive future editions, straight to your inbox. As prediction market trading volume booms, Truist analysts say there could be an unlikely source […]

Read More